Medical & Healthcare apps of Sobi are listed with us

Sobi

Sobi has been involved in the process development and manufacturing of recombinant protein drugs since the technology was first developed more than 30 years ago, then as part of KabiVitrum. Biovitrum was formed in 2001 through the merger of several units of Pharmacia (now Pfizer) and spun off to a consortium of investors led by Nordic Capital and MPM Capital Funds. Operations included a research unit focused on metabolic diseases, a process development unit for protein drugs and a plasma product operation. In 2002 Sobi sold its plasma operation to Octapharma as part of efforts to concentrate operations on protein-based and small molecular drugs.